19 results about "Inhalant Solution" patented technology

The invention relates to a preparation method and application of a traditional Chinese medicine atomization inhalant for diffusing the lung and reducing phlegm, the preparation is prepared from eight medicinal materials including honey ephedra, bitter apricot kernel reformed, aster tataricus and the like through a staged extraction-multi-stage refining-composite stabilization integration process, volatile oil components are subjected to exclusive distillation concentration, non-volatile components are subjected to ethanol-water two-phase extraction, and then the volatile oil components are subjected to ethanol-water two-phase extraction to obtain the traditional Chinese medicine atomization inhalant for diffusing the lung and reducing phlegm. Chitosan flocculation is coupled with precise ultrafiltration to realize deep purification; molecular-level stabilization fusion of volatile oil and a refined water phase is innovatively realized through a composite surfactant system, and finally, a high-stability sterile solution meeting the requirement of an inhalant is prepared. The process overcomes the common problems that a compound traditional Chinese medicine atomized preparation is poor in clarity, effective components are easy to degrade and the atomization performance is poor, and it is ensured that the active components can be efficiently converted into lung targeted deposition superfine aerosol. The product is suitable for respiratory system diseases such as acute bronchitis, asthma turbid phlegm obstructing lung syndrome and the like, and has the advantages of quick response, high local drug concentration and good safety.

The invention belongs to the technical field of antioxidant drugs, and particularly relates to application of a glutathione dry powder inhaler in preparation of drugs for treating radiation acute lung injury, the glutathione dry powder inhaler comprises the following active ingredients by mass percentage: 50%-60% of reduced glutathione, 10%-20% of a carrier and 20%-30% of a dispersant, totaling 100%, the carrier is mannitol, and the dispersing agent is L-leucine. According to the invention, the glutathione dry powder inhalant accurately delivers high-concentration GSH to an alveolar injury area through a lung targeting delivery system, synchronously activates endogenous antioxidant enzymes, inhibits lipid peroxidation and an inflammation source, and blocks release of proinflammatory factors, so that radiation-induced oxidation-inflammation cascade reaction is directly inhibited, alveolar structure damage is relieved, and the anti-inflammatory effect is achieved. And an efficient new treatment strategy is provided for RILI.

The present application relates to a kind of biomimetic lung surfactant carrier, which is prepared from total fat and simulation peptide, in the total fat, the mass ratio of dipalmitoyl phosphatidylcholine, dipalmitoyl phosphatidylglycerol, dipalmitoyl phosphatidyl ethanolamine-polyethylene glycol 2000, cholesterol is 8-12:1:1:1;The lung surfactant simulation peptide is the simulation peptide of SP-B protein and / or the simulation peptide of SP-C protein.The biomimetic lung surfactant carrier has the advantages of high loading rate and high stability.The present application also relates to inhalation dosage form of drug for treating pulmonary arterial hypertension loaded by the biomimetic lung surfactant carrier, which makes the loaded drug obtain more uniform intra-pulmonary distribution, the inhalation drug is more close to natural lung surfactant in composition and physiological function, can delay the degradation of product, improve the utilization rate of drug, achieve good pulmonary arterial hypertension treatment effect.

The invention relates to the field of pharmacy, and particularly provides a method for treating cerebral apoplexy by using fluvoxamine. The invention proves that the fluvoxamine can be used for treating cerebral arterial thrombosis and has multiple effects. The invention also discloses an inhalant for treating cerebral arterial thrombosis. The inhalant comprises an effective amount of fluvoxamine.

The invention provides a polypeptide coupling medicine and application thereof. The polypeptide coupling medicine comprises antiviral polypeptide, connecting polypeptide, amino acid and ambroxol which are connected in sequence. The polypeptide coupling drug provided by the invention is obtained by coupling a coronavirus membrane fusion inhibitor and ambroxol, and is formed by coupling polypeptide serving as a targeting carrier and a load drug through a connexon via a covalent bond. Through polypeptide coupled drug activity evaluation and pharmacokinetic research, evaluation of activity changes of polypeptide and ambroxol and research on drug exposure and half-life periods of inhalants and injections, the polypeptide coupled drug retains antiviral activity of polypeptide and phlegm eliminating / respiratory tract regulating functions of ambroxol, the drug exposure is increased, and the half-life period is prolonged.

The invention discloses a lipid composition containing saccharides or derivatives thereof and application of the lipid composition in enhancing nucleic acid transfection and disease treatment. The composition comprises (a) an active agent or a therapeutic agent containing nucleic acid; (b) a saccharide or a derivative thereof added in an amount of about 0.5-60 wt% of the total weight of the composition; (c) a cationic lipid; (d) a non-cationic lipid; and (e) a lipid conjugate. The composition can significantly improve the biological effect of the nucleic acid therapeutic agent and improve the biological effect of the nucleic acid therapeutic agent for treating or preventing diseases. The pharmaceutical composition can be applied to prevention or treatment of immune system diseases, cancers, virus infection, bacterial infection, metabolic diseases or hereditary diseases and the like, and the dosage forms comprise inhalant, nasal spray, freeze-dried powder, injection or solution.

The application relates to the technical field of pharmaceutical preparations, and discloses an agomelatine inhalant as well as a preparation method and application thereof. The agomelatine inhalant provided by the application comprises agomelatine or a pharmaceutically acceptable salt thereof in a form capable of being inhaled or capable of being changed into a form capable of being inhaled after being excited. From the aspect of synergism, the inhalant can avoid first-pass metabolism by changing a drug administration route, significantly improve bioavailability, and realize rapid effect by directly entering blood from the lung; from the aspect of attenuation, the inhalant can greatly reduce a drug usage amount to achieve a same treatment effect as a tablet, significantly reduce occurrence of drug toxic and side reactions, and significantly reduce liver toxicity by avoiding liver metabolism.

The invention belongs to the technical field of antioxidant drugs, and particularly relates to a glutathione dry powder inhalant as well as a preparation method and application thereof. The glutathione dry powder inhalant is prepared from the following active ingredients in percentage by mass: 50%-60% of reduced glutathione, 10%-20% of a carrier and 20%-30% of a dispersing agent, totaling 100%, the carrier is mannitol, lactose or trehalose, the dispersing agent is leucine, and no other pharmaceutic adjuvants exist. The glutathione dry powder inhalant is obtained by uniformly mixing the raw materials of the glutathione dry powder inhalant and then carrying out spray drying.

Provided is a ventilator that includes a breathing system, a mechanical system coupled to breathing system, and a control system coupled to breathing system and mechanical system. The control system includes pressure sensors, processing circuitry, and memory configured to store a look-up table. The processing circuitry receives a set of values for plurality of parameters, identifies a compression value from a plurality of compression values in the look-up table based on the received set of values. The processing circuitry causes the mechanical system to compress a bag valve of the breathing system in accordance with the identified compression value. The compression of the bag valve causes a gaseous inhalant to flow through the breathing system within a time-interval. The processing circuitry determines an actual volume of the gaseous inhalant and iteratively modifies the compression value of the bag valve to match a desired volume of the gaseous inhalant.

The invention belongs to the field of pharmaceutical preparations, and discloses a long-acting dry powder microsphere inhalant as well as a preparation method and application thereof. The inhalant is a long-acting dry powder microsphere inhalant prepared by taking a mixture of multi-cystic vesicles prepared from phospholipid and a dry powder auxiliary material as a drug carrier and entrapping active ingredients for treating lung diseases through a spray drying technology. Compared with a dry powder microsphere inhalant prepared from traditional monocystic lipidosome, the long-acting dry powder microsphere inhalant has a longer-time slow-release effect. According to the preparation, a unique process of firstly preparing multi-capsule vesicles and then performing spray drying is adopted, the obtained microspheres have an aerodynamic particle size of 1-5 microns, can be effectively deposited in the lung and show a remarkable long-acting slow-release characteristic, and the cumulative release rate reaches about 64% after 48-hour in-vitro release. Compared with a traditional monocystic liposome inhalant, the drug action time is effectively prolonged, the administration frequency is reduced, and the patient compliance is improved. The invention provides a new thought for the research of a pulmonary drug delivery system, and has a wide clinical application prospect.

The invention discloses an exercise physiological monitoring and intelligent dosing integrated protector device which comprises a chest fixing band and a shoulder fixing band. The shoulder fixing band is movably installed on one side of the chest fixing band, a containing disc is fixedly arranged in the middle of the chest fixing band, and sensors used for monitoring breathing, heart rate and blood oxygen of a user are arranged at the rear end of the containing disc; by means of the multiple sensors, the physiological indexes of a user during exercise can be monitored, the conditions of breathing, heart rate, blood oxygen and the like of the user are monitored, and different physiological indexes are monitored, so that whether the user is about to have the illness condition or not is judged, and the early warning function can be achieved; meanwhile, the nasal cavity spray head used for aerosol inhalation is wound on the containing disc, and the inhalant can be supplied to the asthma patient for inhalation through the nasal cavity spray head.

The present invention relates to an inhalation composition comprising a GLP-1 analogue and a transport carrier. The inhalation composition has high stability due to containing a small amount of impurities while having a high effective particle delivery capacity relative to the content of the composition, and has excellent flowability and fillability. In addition, the inhalation composition according to the present invention has high bioavailability compared to oral preparations due to delivering peptides directly to the lungs, and thus can reduce manufacturing costs by reducing the required dosage compared to oral preparations.

The invention provides naringin dry powder inhalation as well as a preparation method and application thereof, belongs to the technical field of pharmaceutical preparations, and particularly provides the naringin dry powder inhalation which comprises the following components in parts by mass: 1-30 parts of micronized naringin and 40-100 parts of a diluent, and the particle size distribution D90 of the micronized naringin is 1-30 [mu] m. The naringin dry powder inhalation provided by the invention is an inhalation administration preparation, has the advantages of high drug absorption rate and quick response, and the naringin dry powder inhalation provided by the invention has extremely low bitter taste and good patient compliance, and can be used for preparing an anti-inflammatory drug inhalant and / or a lung disease treatment drug.

The present invention relates to an inhalation composition comprising a GLP-1 analogue and a transport carrier. The inhalation composition has content stability and thermal stability while having a high effective particle delivery amount relative to content. In addition, the inhalable composition of the present invention directly delivers the peptide to the lungs, and thus has a bioavailability higher than that of oral agents. Therefore, manufacturing costs can be lowered through a reduction in required administration amount compared to that of oral agents.

This invention discloses a method for preparing a bumetanide nasal administration formulation and its application in the treatment of epilepsy, belonging to the field of pharmaceutical technology. The nasal administration formulation is a bumetanide nasal spray and / or a bumetanide dry powder inhaler. The drug is used for immediate administration intervention within 30 minutes after an epileptic seizure in non-medical settings, including at home, outdoors, or during transport. In this invention, the bumetanide nasal spray or dry powder inhaler does not require intravenous puncture or operation by professional medical personnel. Patients or their families can administer the drug directly through the nasal cavity within 30 minutes after an epileptic seizure at home, outdoors, or during transport, breaking through the dependence of traditional intravenous injection on medical settings and equipment, and buying valuable time for neuronal resuscitation.

A method for estimating an inhale dose when a drug is delivered to a person using an inhaler is disclosed. A predicted inhale dose (PID) of the drug is estimated based on at least one first-type parameter and at least one second-type parameter. The first-type parameter is related to a breath pattern of the person, and the second-type parameter is related to the inhaler.

A liquid propellant-free pharmaceutical preparation including treprostinil is provided. The pharmaceutical preparation can undergo a better nebulization effect in a soft mist inhaler than the existing treprostinil preparations. In addition, the active substance in the pharmaceutical preparation is stable during a storage period of 1 to 2 years or longer.

The invention relates to application of an RIPK2 inhibitor GSK2983559 in preparation of drugs for preventing, treating and / or relieving pulmonary fibrosis, a novel strategy with great potential is provided for development of novel anti-pulmonary fibrosis drugs, GSK2983559 is clear in chemical structure and good in stability, can be easily prepared into various dosage forms such as injections and aerosol inhalers, can be applied to whole-body administration and local treatment, and can be applied to preparation of drugs for preventing, treating and / or relieving pulmonary fibrosis. The method is suitable for pulmonary fibrosis patients at different stages, and has good clinical transformation prospects and industrialization feasibility.